Shai Lankry
Chief Financial OfficerMr. Shai Lankry, CPA, MBA, is Chief Financial Officer of Vibrant Ltd. Mr. Lankry has M.B.A. in Finance from Tel Aviv University. He served as Chief Financial Officer at Gamida Cell Ltd. since April 2018 until May 2023. Mr. Lankry is Chief Financial Officer of Purple Biotech Ltd from May 2025. Mr. Lankry has many years of senior management experience in finance. Prior to joining Gamida Cell, from 2016 to 2018, Mr. Lankry served as a Finance Director at West Pharmaceutical Services Inc., leading the R&D and operations financials for the Israeli subsidiary. Mr. Lankry served as Chief Financial Officer at Macrocure Ltd. since February 12, 2016. Mr. Lankry served as Vice President of Finance and Israeli Site Manager at Macrocure Ltd. from 2014 to 2017. Mr. Lankry served as the Chief Financial Officer and Israel Site Manager at Macrocure Ltd. since December 2013 until 2017 and served as its Principal Accounting Officer. From 2006 to 2013, Mr. Lankry worked at Omrix Biopharmaceuticals, Inc., a division of Ethicon Biosurgery, a Johnson & Johnson company, where he served as Biologics Cluster Finance Director, where he managed the finance biologics organization at multiple sites worldwide. From 2004 to 2006, he was a Senior Associate in the audit practice, specializing in high-tech industry, for Kesselman & Kesselman, a member of PriceWaterhouseCoopers International Limited. Mr. Lankry is a Certified Public Accountant (Israeli) and earned an MBA in Finance from Tel-Aviv University in Israel.
Positions
- Company NamePurple Biotech LtdStock CodePPBTPositionChief Financial OfficerColleagues
- IIIsaac IsraelInterim Chief Executive Officer & Director
- EKEric K. RowinskyIndependent Chairman of the Board
- GEGil EfronHead of Corporate Development & Executive Director
- MSMichael SchicklerHead of Clinical & Regulatory Affairs
- IAIdo AgmonIndependent Director
- SNSuzana Nahum-ZilberbergIndependent Director
